Adaptimmune Therapeutics plc
Open: 2:02 PM
ADAP Stock Price Graph
ADAP Stock Price Today
Adaptimmune Therapeutics plc (ADAP) stock declined over -4.40% intraday to trade at $0.5449 a share on NASDAQ. The stock opened with a loss of -0.21% at $0.57 and touched an intraday high of $0.58, falling -4.40% against the last close of $0.57. The Adaptimmune Therapeutics plc in stock market went to a low of $0.55 during the session.
ADAP Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
ADAP Stock Price History Chart
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Frequently Asked Questions
What is the current Adaptimmune Therapeutics plc (ADAP) stock price?
Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock price is $0.54 in the last trading session. During the trading session, ADAP stock reached the peak price of $0.58 while $0.55 was the lowest point it dropped to. The percentage change in ADAP stock occurred in the recent session was -4.40% while the dollar amount for the price change in ADAP stock was -$0.03.
ADAP's industry and sector of operation?
The NASDAQ listed ADAP is part of Biotechnology industry that operates in the broader Healthcare sector. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Who are the executives of ADAP?
Dr. Juli P. Miller Ph.D.
Vice President of Investor Relations
Mr. Adrian G. Rawcliffe
Chief Executive Officer, Principal Accounting Officer & Director
Ms. Margaret Henry
Head of PR & Company Sec.
Ms. Kerry Sharp
Senior Vice President & Gen. Council
How ADAP did perform over past 52-week?
ADAP's closing price is 0.38% higher than its 52-week low of $0.55 where as its distance from 52-week high of $2.65 is -0.48%.
How many employees does ADAP have?
Number of ADAP employees currently stands at N/A. ADAP operates from 60 Jubilee Avenue, Abingdon, OX14 4RX, GB.
Link for ADAP official website?
Official Website of ADAP is: https://www.adaptimmune.com
How do I contact ADAP?
How many shares of ADAP are traded daily?
ADAP stock volume for the day was 263091.00 shares. The average number of ADAP shares traded daily for last 3 months was 432.45 Thousands.
What is the market cap of ADAP currently?
The market value of ADAP currently stands at $123.65 Million with its latest stock price at $0.54 and N/A of its shares outstanding.